JDRF’s philanthropic venture capital fund is focused on accelerating life-changing solutions to cure, prevent, and treat type 1 diabetes through catalytic commercial investment. It’s a unique solution that Fund Managing Director Katie Ellias believes will help spur innovation and bring new, disease-modifying therapies to patients more quickly.Subscribe now to read the full analysis
Welcome to MyStrategist, an online experience like no other in the medical device industry.
With MyStrategist, quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and MedTech Strategist Market Pathways – now on an all-in-one, digital platform. We invite you to explore our coverage.
Think Strategically. Subscribe Today.
Discover the opportunities and challenges that impact the global medtech regulatory and reimbursement community with MedTech Strategist Market Pathways.Subscribe Free Premier Issue Learn More
Innovation Summit San Francisco, November 18-19th, is coming soon. Early-bird registration expires Sept. 30th!Register Learn More
As the increasing search for innovation continues, medtech companies hoping to expand globally should take advantage of three key macro drivers for cross-border M&A. By Sundeep Lal, Senior Managing Director and Head of Healthcare & Life Sciences, Auctus Capital Partners.Subscribe now to read the full analysis